{
  "trial_id": "NCT02315716",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Previously untreated patients with symptomatic MM",
      "label": "met",
      "evidence": "appendix 3"
    },
    {
      "criterion": "Suitable for high dose therapy and ASCT",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Age \u2265 18 years",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Life expectancy \u2265 3 months",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Measurable disease as defined by one of the following:",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Secretory myeloma: Monoclonal protein in the serum (\u226510 g/L) or monoclonal light chain in the urine (Bence Jones protein \u2265200mg/24hours), or serum free light chain (SFLC, involved light chain \u2265100mg/L provided the FLC ratio is abnormal)",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Non-secretory myeloma: Either \u226530% clonal plasma cells in bone marrow (aspirate or trephine) Or 10-30% clonal plasma cells in the marrow and >1 soft tissue or extra-osseous plasmacytoma \u2265 2 cm that is measurable for response assessment by CT or MRI",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Adequate hepatic function, with serum ALT \u2264 3.5 times the upper limit of normal and serum direct bilirubin \u2264 2 mg/dL (34 \u00b5mol/L) within 14 days prior to registration",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Absolute neutrophil count (ANC) \u2265 1.0 \u00d7 10^9/L within 14 days prior to registration and subject has not received any growth factor support within 7 days of testing.",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "ANC\u22650.8x10^9/L allowed for patients with racial neutropenia.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Haemoglobin \u2265 8 g/dL (80 g/L) within 14 days prior to registration (subjects may be receiving red blood cell (RBC) transfusions in accordance with institutional guidelines)",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Platelet count \u2265 75 \u00d7 10^9/L (\u2265 50 \u00d7 10^9/L if myeloma involvement in the bone marrow is > 50%) within 14 days prior to registration and subject has not received any platelet transfusions within 7 days prior to testing.",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Creatinine clearance (CrCl) \u2265 30 mL/minute within 14 days prior to registration, either measured or calculated using a standard formula (e.g. Cockcroft and Gault).",
      "label": "met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant or breast-feeding females",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Previous systemic chemotherapy for myeloma, with the exception of steroids",
      "label": "not_met",
      "evidence": ""
    }
  ],
  "notes": "Patient has multiple myeloma with recurrent disease and systemic amyloidosis. She is on hemodialysis for ESRD and represents with malaise, weakness, and generalized body aching.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT02315716",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}